Identification of novel candidate protein biomarkers for the post-polio syndrome - Implications for diagnosis, neurodegeneration and neuroinflammation

Journal of Proteomics

Volumn 71, Issue 6, 2009, Pages 670-681

  Gonzalez, Henrik ^a   Ottervald, Jan ^b,d   Nilsson, Kerstin C ^b   Sjögren, Niclas ^b   Miliotis, Tasso ^c   Von Bahr, Helena ^c   Khademi, Mohsen ^d   Eriksson, Bodil ^b   Kjellström, Sven ^c   Vegvari, Akos ^c   Harris, Robert ^d   Marko Varga, György ^c   Borg, Kristian ^a   Nilsson, Johan ^e   Laurell, Thomas ^e   Olsson, Tomas ^d   Franzén, Bo ^b  

^a Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Biomarkers; CSF; Diagnosis; Pathophysiology; Post polio syndrome; Proteomics

Indexed keywords

ALPHA AMIDATING ENZYME; GELSOLIN; GLUTATHIONE SYNTHASE; HEMOPEXIN; KALLIKREIN 6;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; POSTPOLIOMYELITIS SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS;

EID: 58649098959     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2008.11.014     Document Type: Article

References (61)

1. Trojan D.A., and Cashman N.R. Post-poliomyelitis syndrome. Muscle Nerve 31 1 (2005) 6-19
2. Farbu E., Gilhus N.E., Barnes M.P., Borg K., de Visser M., Driessen A., et al. EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol 13 8 (2006) 795-801
3. McComas A.J., Quartly C., and Griggs R.C. Early and late losses of motor units after poliomyelitis. Brain 120 Pt 8 (1997) 1415-1421
4. Grimby G., Stålberg E., Sandberg A., and Sunnerhagen K.S. An 8-year longitudinal study of muscle strength, muscle fiber size, and dynamic electromyogram in individuals with late polio. Muscle Nerve 21 11 (1998) 1428-1437
5. Bartholdi D., Gonzalez H., Borg K., and Melki J. Absence of SMN gene deletion in post-polio syndrome. Neuromuscul Disord 10 2 (2000) 99
6. Cashman N.R., and Trojan D.A. Correlation of electrophysiology with pathology, pathogenesis, and anticholinesterase therapy in post-polio syndrome. Ann N Y Acad Sci 753 (1995) 138-150
7. Dalakas M., and Illa I. Post-polio syndrome: concepts in clinical diagnosis, pathogenesis, and etiology. Adv Neurol 56 (1991) 495-511
8. Dalakas M.C. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 753 (1995) 167-185
9. Dalakas M.C. Pro-inflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome?. J Neurol Sci 205 1 (2002) 5-8
10. Dalakas M.C., Sever J.L., Madden D.L., Papadopoulos N.M., Shekarchi I.C., Albrecht P., et al. Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies. Rev Infect Dis 6 Suppl 2 (1984) S562-S567
11. Dinsmore S., Dambrosia J., and Dalakas M.C. A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann N Y Acad Sci 753 (1995) 303-313
12. Halstead L.S. Post-polio syndrome. Sci Am 278 4 (1998) 42-47
13. Leon-Monzon M.E., Illa I., and Dalakas M.C. Expression of poliovirus receptor in human spinal cord and muscle. Ann N Y Acad Sci 753 (1995) 48-57
14. Pelletier I., Duncan G., Pavio N., and Colbére-Garapin F. Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Cell Mol Life Sci 54 12 (1998) 1385-1402
15. Rekand T., et al. Fcgamma receptor IIIA polymorphism as a risk factor for acute poliomyelitis. J Infect Dis 186 12 (2002) 1840-1843
16. Roivainen M., Kinnunen E., and Hovi T. Twenty-one patients with strictly defined postpoliomyelitis syndrome: no poliovirus-specific IgM antibodies in the cerebrospinal fluid. Ann Neurol 36 1 (1994) 115-116
17. Sharief M.K., Hentges R., and Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N Engl J Med 325 11 (1991) 749-755
18. Farbu E., Rekand T., Vik-Mo E., Lygren H., Gilhus N.E., and Aarli J.A. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol 14 1 (2007) 60-65
19. Fordyce C.B., Gagne D., Jalili F., Alatab S., Arnold D.L., Da Costa D., et al. Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 271 1-2 (2008) 80-86
20. Zerr I., et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 348 9031 (1996) 846-849
21. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., and Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118 1-2 (2003) 140-146
22. Choe L.H., et al. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23 14 (2002) 2247-2251
23. Halstead L.S., and Rossi C.D. Post-polio syndrome: clinical experience with 132 consecutive outpatients. Birth Defects Orig Artic Ser 23 4 (1987) 13-26
24. Gonzalez H., Khademi M., Andersson M., Piehl F., Wallström E., Borg K., et al. Prior poliomyelitis-IvIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150 1-2 (2004) 139-144
25. Newcombe J., Eriksson B., Ottervald J., Yang Y., and Franzén B. Extraction and proteomic analysis of proteins from normal and multiple sclerosis postmortem brain. J Chromatogr B Analyt Technol Biomed Life Sci 815 1-2 (2005) 191-202
26. Berggren K., Chernokalskaya E., Steinberg T.H., Kemper C., Lopez M.F., Diwu Z., et al. Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfate-polyacrylamide gels using a luminescent ruthenium complex. Electrophoresis 21 12 (2000) 2509-2521
27. Wold S., Sjostrom M., and Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometr Intell Lab Syst 58 (2001) 109-130
28. Ambroise C., and McLachlan G.J. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 99 10 (2002) 6562-6566
29. Wallman L., Ekström S., Marko-Varga G., Laurell T., and Nilsson J. Autonomous protein sample processing on-chip using solid-phase microextraction, capillary force pumping, and microdispensing. Electrophoresis 25 21-22 (2004) 3778-3787
30. Leifeld L., et al. Anti-apoptotic function of gelsolin in fas antibody-induced liver failure in vivo. Am J Pathol 168 3 (2006) 778-785
31. Baumann H., and Gauldie J. The acute phase response. Immunol Today 15 2 (1994) 74-80
32. Scarisbrick I.A., Towner M.D., and Isackson P.J. Nervous system-specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 17 21 (1997) 8156-8168
33. Bernett M.J., Blaber S.I., Scarisbrink I.A., Dhanarajan P., Thompson S.M., and Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 277 27 (2002) 24562-24570
34. Blaber S.I., et al. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41 4 (2002) 1165-1173
35. Bolkenius F.N., and Ganzhorn A.J. Peptidylglycine alpha-amidating mono-oxygenase: neuropeptide amidation as a target for drug design. Gen Pharmacol 31 5 (1998) 655-659
36. Tsukamoto T., Noguchi M., Kayama H., Watanabe T., Asoh T., and Yamamoto T. Increased peptidylglycine alpha-amidating monooxygenase activity in cerebrospinal fluid of patients with multiple sclerosis. Intern Med 34 4 (1995) 229-232
37. Meister A., and Anderson M.E. Glutathione. Annu Rev Biochem 52 (1983) 711-760
38. Gonzalez H., Khademi M., Andersson M., Wallström E., Borg K., and Olsson T. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 205 1 (2002) 9-13
39. Gonzalez H., Stibrant Sunnerhagen K., Sjöberg I., Kaponides G., Olsson T., and Borg K. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5 6 (2006) 493-500
40. Scarisbrick I.A., Sabharwal P., Cruz H., Larsen N., VAndell A.G., Blaber S.I., et al. Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur J Neurosci 24 5 (2006) 1457-1469
41. Scarisbrick I.A., Blaber S.I., Luccinetti C.F., Genain C.P., Blaber M., and Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain 125 Pt 6 (2002) 1283-1296
42. Blaber S.I., Ciric B., Christophi G.P., Bernett M.J., Blaber M., Rodriguez M., et al. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. Faseb J 18 7 (2004) 920-922
43. Diamandis E.P., Yousef G.M., Petraki C., and Soosaipillai A.R. Human kallikrein 6 as a biomarker of alzheimer's disease. Clin Biochem 33 8 (2000) 663-667
44. Scarisbrick I.A., Blaber S., Tingling J., Rodriguez M., Blaber M., and Christophi G. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol 178 1-2 (2006) 167-176
45. Mitka M. Aging brings new challenges for polio survivors. Jama 296 14 (2006) 1718-1719
46. Kothakota S., Azuma T., Reinhard C., Klippel A., Tang J., Chu K., et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278 5336 (1997) 294-298
47. Geng Y.J., Azuma T., Tang J.X., hartwig J.H., Muszynski M., Wu Q., et al. Caspase-3-induced gelsolin fragmentation contributes to actin cytoskeletal collapse, nucleolysis, and apoptosis of vascular smooth muscle cells exposed to proinflammatory cytokines. Eur J Cell Biol 77 4 (1998) 294-302
48. Kusano H., Shimizu S., Koya R.C., Fujita H., Kamada S., Kuzumaki N., et al. Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 19 42 (2000) 4807-4814
49. Ogata Y., Charlesworth M.C., and Muddiman D.C. Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid. J Proteome Res 4 3 (2005) 837-845
50. Tolosano E., and Altruda F. Hemopexin: structure, function, and regulation. DNA Cell Biol 21 4 (2002) 297-306
51. Madore N., Camborieux L., Bertrand N., and Swerts J.P. Regulation of hemopexin synthesis in degenerating and regenerating rat sciatic nerve. J Neurochem 72 2 (1999) 708-715
52. Bakker W.W., van Dael C.M., Pierik L.J., van Wijk J.A., Nauta J., Borghuis T., et al. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr Nephrol 20 10 (2005) 1410-1415
53. Castano E.M., Roher A.E., Esh C.L., Kokjohn T.A., and Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28 2 (2006) 155-163
54. Qiao H., Koya R., Nakagawa K., Tanaka H., Fujita H., Takimoto M., et al. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 26 6 (2005) 849-855
55. Pezeshkpour G.H., and Dalakas M.C. Pathology of spinal cord in post-poliomyelitis muscular atrophy. Birth Defects Orig Artic Ser 23 4 (1987) 229-236
56. Pezeshkpour G.H., and Dalakas M.C. Long-term changes in the spinal cords of patients with old poliomyelitis. Signs of continuous disease activity. Arch Neurol 45 5 (1988) 505-508
57. Ikemoto A., and Hirano A. Immunohistochemical studies on clustered pericapillary bodies in the spinal cord of post-poliomyelitis patients. Acta Neuropathol (Berl) 92 2 (1996) 164-169
58. Dalakas M.C. Morphologic changes in the muscles of patients with postpoliomyelitis neuromuscular symptoms. Neurology 38 1 (1988) 99-104
59. Lundberg C., Lidman O., Holmdahl R., Olsson T., and Piehl F. Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains. J Comp Neurol 431 1 (2001) 75-87
60. Lidman O., Swanberg M., Horvath L., Broman K.W., Olsson T., and Piehl F. Discrete gene loci regulate neurodegeneration, lymphocyte infiltration, and major histocompatibility complex class II expression in the CNS. J Neurosci 23 30 (2003) 9817-9823
61. Swanberg M., Lidman O., Padyukov L., Eriksson P., Åkesson E., Jagodic M., et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 37 5 (2005) 486-494